PBIG.F logo

Paradigm Biopharmaceuticals OTCPK:PBIG.F Stock Report

Last Price

US$0.23

Market Cap

US$84.9m

7D

0%

1Y

-73.7%

Updated

21 Mar, 2024

Data

Company Financials +

Paradigm Biopharmaceuticals Limited

OTCPK:PBIG.F Stock Report

Market Cap: US$84.9m

PBIG.F Stock Overview

Paradigm Biopharmaceuticals Limited engages in the research and development of therapeutic products for human use in Australia.

PBIG.F fundamental analysis
Snowflake Score
Valuation3/6
Future Growth3/6
Past Performance0/6
Financial Health4/6
Dividends0/6

Paradigm Biopharmaceuticals Limited Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Paradigm Biopharmaceuticals
Historical stock prices
Current Share PriceAU$0.23
52 Week HighAU$0.95
52 Week LowAU$0.20
Beta0.92
1 Month Change0%
3 Month Changen/a
1 Year Change-73.72%
3 Year Changen/a
5 Year Changen/a
Change since IPO-77.79%

Recent News & Updates

Recent updates

Shareholder Returns

PBIG.FUS BiotechsUS Market
7D0%-1.7%1.0%
1Y-73.7%12.6%31.2%

Return vs Industry: PBIG.F underperformed the US Biotechs industry which returned 12.6% over the past year.

Return vs Market: PBIG.F underperformed the US Market which returned 31.2% over the past year.

Price Volatility

Is PBIG.F's price volatile compared to industry and market?
PBIG.F volatility
PBIG.F Average Weekly Movementn/a
Biotechs Industry Average Movement11.8%
Market Average Movement6.0%
10% most volatile stocks in US Market16.6%
10% least volatile stocks in US Market3.0%

Stable Share Price: PBIG.F has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine PBIG.F's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
2014n/aPaul Renniehttps://www.paradigmbiopharma.com

Paradigm Biopharmaceuticals Limited engages in the research and development of therapeutic products for human use in Australia. It offers pentosan polysulfate sodium drugs in the injectable form for the treatment of osteoarthritis, mucopolysaccharidosis, ross river virus, chikungunya virus, chronic heart failure, allergic respiratory, and acute respiratory distress syndrome diseases. The company was incorporated in 2014 and is based in Melbourne, Australia.

Paradigm Biopharmaceuticals Limited Fundamentals Summary

How do Paradigm Biopharmaceuticals's earnings and revenue compare to its market cap?
PBIG.F fundamental statistics
Market capUS$84.90m
Earnings (TTM)-US$45.70m
Revenue (TTM)US$27.85k

3,090x

P/S Ratio

-1.9x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
PBIG.F income statement (TTM)
RevenueAU$42.05k
Cost of RevenueAU$11.47k
Gross ProfitAU$30.58k
Other ExpensesAU$69.03m
Earnings-AU$69.00m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-0.20
Gross Margin72.73%
Net Profit Margin-164,092.68%
Debt/Equity Ratio0%

How did PBIG.F perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.